Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.

• Revenue in USD (TTM)0.00
• Net income in USD-5.87m
• Incorporated2015
• Employees3.00

• Location
  Avenue Therapeutics Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
• Phone+1 (781) 652-4500
• Fax+1 (302) 531-3150
• Websitehttps://avenuetx.com/